Shanghai Ambrosia has established a series of novel disease-targeting drug screening assays.  These assays were uniquely designed to target new components of key disease-related cell signaling systems.  These platforms provide a multi-level selection system to identify and to evaluate drug candidates targeting cancer and immune diseases.